Mereo BioPharma Group PLC
MREO
Company Profile
Business description
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Contact
One Cavendish Place
4th Floor
LondonW1G 0QF
GBRT: +44 3330237300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.40 | 59.90 | 0.67% |
| CAC 40 | 7,744.41 | 53.81 | -0.69% |
| DAX 40 | 24,041.90 | 265.90 | -1.09% |
| Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
| FTSE 100 | 9,023.81 | 10.82 | 0.12% |
| HKSE | 25,470.77 | 340.74 | 1.36% |
| NASDAQ | 20,892.69 | 81.49 | -0.39% |
| Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
| NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
| S&P 500 | 6,309.62 | 4.02 | 0.06% |
| S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
| SSE Composite Index | 3,583.12 | 1.26 | 0.04% |